Cowen & Co. analyst Yaron Werber maintained a Buy rating on Argenx Se (ARGX) today. The company’s shares closed last Monday at $116.73.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 7.2% and a 56.0% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Springworks Therapeutics Inc, and Rocket Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $157.66 average price target, implying a 31.9% upside from current levels. In a report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $154.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $150.92 and a one-year low of $71.48. Currently, Argenx Se has an average volume of 155.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia.
